高剂量化疗和自体造血干细胞移植治疗结节性淋巴细胞为主型霍奇金淋巴瘤。
High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.
机构信息
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
出版信息
Biol Blood Marrow Transplant. 2013 Jun;19(6):991-4. doi: 10.1016/j.bbmt.2013.03.008. Epub 2013 Mar 16.
Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.
摘要
结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）是一种独特的霍奇金淋巴瘤亚型，其特征为独特的临床表现、组织学表现和惰性疾病过程。疾病的复发性为研究其治疗中干细胞移植的作用提供了机会。我们在此报告了 1990 年至 2008 年间，26 例复发性 NLPHL 患者接受大剂量化疗和自体干细胞移植的单中心经验。中位随访时间为 50 个月（范围，2-138 个月），5 年总生存率和无事件生存率分别为 76%（SE 10%）和 69%（SE 10%）。我们的数据表明，对于复发性 NLPHL 患者，大剂量化疗和自体移植应被视为一种选择。
相似文献
1
High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.
Biol Blood Marrow Transplant. 2013 Jun;19(6):991-4. doi: 10.1016/j.bbmt.2013.03.008. Epub 2013 Mar 16.
2
High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Ann Hematol. 2016 Jan;95(1):49-54. doi: 10.1007/s00277-015-2527-4.
3
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Am J Hematol. 2018 Jan;93(1):40-46. doi: 10.1002/ajh.24927. Epub 2017 Nov 9.
4
High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
Leuk Lymphoma. 2006 Aug;47(8):1504-10. doi: 10.1080/10428190600573291.
5
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
Am J Hematol. 2019 Nov;94(11):1208-1213. doi: 10.1002/ajh.25607. Epub 2019 Aug 21.
6
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
Curr Opin Oncol. 2021 Sep 1;33(5):395-399. doi: 10.1097/CCO.0000000000000774.
7
Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
Expert Rev Hematol. 2023 Jul-Dec;16(8):607-615. doi: 10.1080/17474086.2023.2226859. Epub 2023 Jun 20.
8
How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Blood. 2020 Dec 24;136(26):2987-2993. doi: 10.1182/blood.2019004044.
9
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.
10
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31.
引用本文的文献
1
Long-Term Results of Hematopoietic Cell Transplantation (HCT) for Adults with Blood Disorders- A Systematic Review.
Stem Cell Rev Rep. 2025 Jun 18. doi: 10.1007/s12015-025-10912-w.
2
Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Cancers (Basel). 2023 Jun 23;15(13):3310. doi: 10.3390/cancers15133310.
3
Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.
BMC Cancer. 2021 Apr 1;21(1):351. doi: 10.1186/s12885-021-08074-2.
4
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):324-328. doi: 10.1182/asheducation-2017.1.324.
5
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.
Leukemia. 2016 Jun;30(6):1425-7. doi: 10.1038/leu.2015.321. Epub 2015 Nov 20.
6
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1.
7
The GHSG Approach to Treating Hodgkin's Lymphoma.
Curr Hematol Malig Rep. 2015 Sep;10(3):256-65. doi: 10.1007/s11899-015-0262-5.
本文引用的文献
1
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Blood. 2011 Oct 27;118(17):4585-90. doi: 10.1182/blood-2011-07-365932. Epub 2011 Aug 26.
2
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Blood. 2011 Oct 20;118(16):4363-5. doi: 10.1182/blood-2011-06-361055. Epub 2011 Aug 9.
3
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
4
Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.
Ann Oncol. 2010 Oct;21(10):2061-2068. doi: 10.1093/annonc/mdq063. Epub 2010 Mar 23.
5
Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
Cancer. 2010 Feb 1;116(3):631-9. doi: 10.1002/cncr.24819.
6
Nodular lymphocyte predominant Hodgkin lymphoma.
Oncologist. 2009 Jul;14(7):739-51. doi: 10.1634/theoncologist.2009-0099. Epub 2009 Jul 15.
7
Management of Hodgkin lymphoma in relapse after autologous stem cell transplant.
Hematology Am Soc Hematol Educ Program. 2008:326-33. doi: 10.1182/asheducation-2008.1.326.
8
Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
J Clin Oncol. 2008 Jan 20;26(3):434-9. doi: 10.1200/JCO.2007.11.8869. Epub 2007 Dec 17.
9
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Blood. 2008 Jan 1;111(1):109-11. doi: 10.1182/blood-2007-03-078725. Epub 2007 Oct 15.
10
Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Hematology Am Soc Hematol Educ Program. 2006:266-72. doi: 10.1182/asheducation-2006.1.266.
Zotero 插件